Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma (Q34633455)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q41784107)
(Q56849196)
(Q32650033)
(P304) 555-567
(P407) (Q1860)
(P433) 2
(P478) 18
(P577) Wednesday, November 2, 2011
(P921) (Q42824440)
(Q181600)
(Q425088)
(P1433) (Q332253)
(P1476) "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma" (language: en)
(P2093) John M Kirkwood
Jeff Sosman
James Larkin
Peter Hersey
Mark Middleton
Mireille Cantarini
Victoria Zazulina
Karin Kemsley
(P2860) (Q24631953)
(Q34629364)
(Q35679353)
(Q27851617)
(Q41703846)
(Q27860458)
(Q38300326)
(Q42466391)
(Q37624337)
(Q37389958)
(Q37453821)
(Q39954401)
(Q27851426)
(Q37048982)
(Q40093939)
(Q36907524)
(Q36002845)
(Q29616397)
(Q36754537)
(Q40164535)
(Q34595700)
(Q40385205)
(Q36191575)
(Q36615986)
(Q28251989)
(Q31034352)
(Q40606325)
(Q28378420)
(Q44004637)
(Q54588857)
(Q54610975)
(Q43152544)
(Q46784012)
(Q78508829)
(Q80901366)
(Q84296085)
other details